{"name":"Neurophth Therapeutics Inc","slug":"neurophth-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQS2E0RVh5TDRmVEV5WUVDUkRGS3BjZ09ZWFhCYmNvaThaNGx3RXE3ektZVmtMWWd3ZUMyaGpEZkN0YzZZT3NHVjhKdGZYSERfWlZOdlpTNW1hRlBEU3l0ZEdZV0VXMTNEZG1BeHY3V1Y1S3BJUDV6bHMyNzRENXVvSDc1UWE2VlJyNVJuRVB2Y2VZOHVJUGV0allSd1M?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com","headline":"Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-05","type":"trial","source":"globenewswire.com","summary":"AAV for the Hereditary Retinal Diseases Clinical Trial - globenewswire.com","headline":"AAV for the Hereditary Retinal Diseases Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWWwxai1rZjNoekk3eGxnYmxoX0dRdXNmMHpHT3k5OWhKcmxZSWNPNHFvVWhJN1dpTnVNUlFXcnRHZ1dnNEttOEZWZXNpcC1fUGxOcEJqcVZXTjdOdm1tQU5vT0ZyX2VQUm02VVktODZNTVVCWjlubC03eGJZbDJTcUNacTNDaEt3N2JiN1h2bi1zY296dDN6VzRueXNtYXdna2FuMTZPNTZRZC1EZXBjUEN6RzhUOUpxT01kTl9ienBZbVE?oc=5","date":"2024-02-20","type":"trial","source":"BioPharma APAC","summary":"Neurophth Completes Enrollment for Opvika® LHON Gene Therapy Trial in the U.S. - BioPharma APAC","headline":"Neurophth Completes Enrollment for Opvika® LHON Gene Therapy Trial in the U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOSFhreEs5b1ZLZloyVTkybDhZYU00RFZTN2d2T0FneVpfS1JvaFhmdHRxaGloU1lVX1l6Yi12OXhqUy1qZ3FjWFl6MVJNbllqOVRlUTA4cVpjNlVtaTVaVVl4czNrMENWVnQtNldLOE95ZXhYY1doenQ1YnZocW1MaUZjT0o5MXNDbmtWRl9UNDlUVTljYVVLeERtT1l6WnVELVNXZWs5ZFFURlFJbEVReGZNU3lPQU5yM0tCMUYxcXp5a0VLTF82WGlYTDJELXQ2cHlyWWRLeWpNMnUtMnoyS2NGMWZQZ3lSdEE?oc=5","date":"2024-02-19","type":"trial","source":"PR Newswire","summary":"Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S. - PR Newswire","headline":"Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8yaWwxX1VvMFdTalpoc3hRNk1abm5KdXFRRlNpQ19sOF9yRmtkNEFyOHZFYWNzR2lyVzVDaW5KallyY0xjM2c5UzhNQVNDaEFaT2l0ZGllTENWeDFaUGJ0b2I5ZGxSNnVWbGhtY0hR?oc=5","date":"2023-11-14","type":"pipeline","source":"Labiotech.eu","summary":"10 biotech companies leading innovation in the Asia-Pacific region - Labiotech.eu","headline":"10 biotech companies leading innovation in the Asia-Pacific region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNWGtoZ3liSm42R3Z3bHRPU2dRU0FlSkhLcjJsOGhCam1YTXVFb1FzZ01VOFpzNW41cVZFblVQbmRhSm9tSE00aTZrZU11Nm5WZkZCejNKOGZ0bzBPcm1Eem95a3labkZBQ0V1VC16YkFweUdLckpfWElzUFVuaXdHN3VhekxYYldqXzRDaXN0MDY4MnFscGhsTUhEbUtueGNIMERtcHlwT1lOUkNwQTNKNEhTOWdoYV9xYi03c3RsN2gtaG9BV0JlMV9aUW5QT095bXNkSlBacjNKYzlaclhyZzJKWjY?oc=5","date":"2023-08-11","type":"trial","source":"PR Newswire","summary":"Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials - PR Newswire","headline":"Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQQjJwNG1ZcmFnRTZQQ1BaNTBVVFRnZVM0STdKeGFIclV1LTZVdk5obk1rV0FiUGpvQS1rb3RWM3lnZENkdkpkdTE1TkJfVlM2cm0wWHpsT2I0cFh6cVVpV05ET2NYSVIxYzRYTVZrV2U1V0szQTd5djdMeklQMTJaTmtidjRrUDlKYUxRMC1QdVl2d0I0dDNkT0tTXzQ2TDhtUU9Gel9adV9PTE8zV1A4aXlheHJnQjMtc1BiQjVJWEVERWcxNFlpYzhSaFFCbGc0LUFfSnVfaWJBdnI3X0JlSnZwcUZacXBxak5GUWh0cnE2d3RF?oc=5","date":"2021-11-24","type":"pipeline","source":"PR Newswire","summary":"Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer - PR Newswire","headline":"Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQOElLV3hYZUFfbWNUcS02V3BGM25KZlY4emM2Umg3bkpyeURPQjRJeW4zQlpGQWRhYXlfdi1BcEpPN1FzT0FaaVpZMzhVQmRHeGZXMUFyVlZOemdDS19ycGVwZjFNXzc3clF6REVvZGt1UWQ5SjZpSnlFUnBId1FxbGE3MjRFemcyWU8xQ0gyc3hKckJIUVZFVEs5Z3daMWZ2dmU4Y0xR?oc=5","date":"2021-01-27","type":"pipeline","source":"Fierce Biotech","summary":"Neurophth Therapeutics snags University of Louisville professor as new CSO - Fierce Biotech","headline":"Neurophth Therapeutics snags University of Louisville professor as new CSO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}